rectal cancer	is a	malignant neoplasm of rectum
anal cancer	is a	malignant neoplasm of anal canal
rectal cancer	has histology	adenocarcinoma
anal cancer	has histology	squamous cell carcinoma
rectal cancer	stage	II-III
anal cancer	stage	I-III
neoadjuvant chemoradiation	used for	rectal cancer
chemoradiation	standard treatment for	anal cancer
total mesorectal excision	is a	surgical technique for rectal cancer
low anterior resection	is a	surgical option for mid-upper rectal cancer
abdominoperineal resection	results in	permanent colostomy
colostomy	affects	anorectal function
circumferential resection margin	predicts	local recurrence
negative margin	indicates	complete tumor clearance
liver metastasis	indicates	distant spread
lung metastasis	indicates	distant spread
bone metastasis	occurs	in advanced disease
MRI pelvis	used for	rectal cancer staging
endoscopic ultrasound	used for	rectal cancer staging
CT chest abdomen pelvis	used for	metastasis evaluation
PET-CT	improves	detection of metastatic disease
CEA	is biomarker for	colorectal cancer
p16	is biomarker for	HPV-driven cancers
HPV infection	associated with	anal cancer
HPV16	associated with	anal cancer
HIV infection	increases risk of	anal cancer
smoking	increases risk of	rectal cancer
age	increases risk of	colorectal cancer
obesity	associated with	colorectal cancer
family history	increases risk of	colorectal cancer
immunosuppression	increases risk of	anal cancer
MSI-H	responds to	pembrolizumab
MSI-H	predicts response to	immunotherapy
KRAS mutation	predicts resistance to	anti-EGFR therapy
NRAS mutation	predicts resistance to	anti-EGFR therapy
BRAF mutation	associated with	poorer prognosis
MMR deficiency	associated with	MSI-H
anal canal	location for	anal cancer
rectum	location for	rectal cancer
neoadjuvant therapy	enables	sphincter-sparing surgery
sphincter-sparing surgery	preserves	continence
abdominoperineal resection	eliminates	anal sphincter
surgical margins	affect	local control
negative circumferential resection margin	improves	local control
adjuvant chemotherapy	reduces	recurrence risk
CAPOX	includes	capecitabine and oxaliplatin
FOLFOX	includes	fluorouracil and oxaliplatin
capecitabine	used with	radiotherapy
5-FU	used with	radiotherapy
mitomycin C	used with	radiotherapy
radiotherapy	used for	anal cancer
radiotherapy	used for	rectal cancer
Nigro protocol	comprises	5-FU and mitomycin C with radiotherapy
watch-and-wait	strategy for	rectal cancer after chemoradiation
pathologic complete response	improves	prognosis
complete clinical response	achieved after	neoadjuvant therapy
hepatic resection	performed for	liver metastasis
hepatic metastasis	managed by	systemic chemotherapy
liver metastasis	most common site of	distant spread in colorectal cancer
lung metastasis	common site of	distant spread in colorectal cancer
resection margin	influences	prognosis
stoma care	requires	education
colostomy	affects	body image
surveillance	includes	periodic imaging
CEA monitoring	tracks	recurrence
tumor regression grade	correlates with	outcome
MRI restaging	guides	surgical planning
tumor burden	reduces with	neoadjuvant therapy
neoadjuvant radiotherapy dose	influences	toxicity
radiation toxicity	impacts	quality of life
anastomotic leak	occurs after	rectal resection
stoma permanence	linked with	abdominoperineal resection
sphincter preservation	improves	quality of life
inguinal lymph node involvement	indicates	advanced disease in anal cancer
tumor grade	influences	prognosis
differentiation	reflects	tumor aggressiveness
clinical trial	evaluates	new therapies for rectal cancer
immunotherapy	effective for	MSI-H colorectal cancer
PD-1 inhibitor	used for	MSI-H colorectal cancer
cetuximab	effective in	KRAS wild-type colorectal cancer
cetuximab	ineffective in	KRAS mutant colorectal cancer
line of therapy	determined by	performance status
performance status	influences	treatment tolerance
colostomy reversal	feasibility	after abdominoperineal resection
colostomy reversal	depends on	tumor response
distant metastasis	increases	mortality
tumor size	correlates with	stage
pathology report	informs	adjuvant therapy decisions
AJCC staging	guides	treatment planning
oncologic clearance	achieved by	mesorectal excision
anal canal	borders	anal verge
rectal cancer	risk factor for	local recurrence
watch-and-wait strategy	requires	rigorous surveillance
pathologic response	defines	prognosis
tumor budding	indicates	aggressive biology
tumor budding	correlates with	recurrence risk
neoadjuvant therapy	associated with	higher complete response rate
adjuvant therapy	associated with	improved disease-free survival
rectal cancer	requires	multidisciplinary care
anal cancer	has favorable outcomes with	chemoradiation
